ORMD-0801 positioned to potentially be the first FDA approved oral insulin for the treatment of diabetes Completed enrollment of 710 patients for the Phase 3 ORA-D-013-1 study Top line data expected in January 2023 NEW YORK, May 3, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: [...]
NEW YORK, April 5, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the European Patent Office has granted the Company the patent titled "Methods and Compositions for Treating NAFLD, Hepatic [...]
NEW YORK, April 4, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Yadin Rozov to its Board of Directors effective April 1, 2022. The Board determined that Mr. [...]
- 76 Percent of the Physicians Responded They "Definitely Would" or "Probably Would" Prescribe Oramed's Oral Insulin Candidate for Type 2 Diabetes Patients NEW YORK, March 29, 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the [...]
Wednesday, March 30, 2022, at 12:00 p.m. ET NEW YORK, March 22, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that it will host a webinar with Key [...]
- Topline results expected H2 2022 - ORMD-0801 is the first oral insulin to be evaluated as a treatment for NASH - Currently no FDA approved therapy exists for NASH NEW YORK, March 16, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP), (TASE: ORMP), a [...]
NEW YORK, March 10, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present a live company overview at the Barclays Global Healthcare Conference, [...]
- Oral insulin program continues to advance with topline efficacy data expected in H2 2022 - Significant value creation opportunities through oral COVID-19 vaccine program and partnerships - Well positioned to capitalize on opportunities with strong cash balance of ~$174 million as of December 3, [...]
- Protease inhibitor is a key component of Oramed's PODTM technology that protects therapeutic proteins in the digestive system - Oramed has already been granted this patent in the United States and Japan NEW YORK, Jan. 5, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) [...]
Initial pre-purchase of 10 million doses of oral vaccines with a potential deal for further orders worth hundreds of millions of dollars Prospective patient population of approximately 660 million throughout the Association of Southeast Asian Nations NEW YORK, Dec. 29, 2021 /PRNewswire/ -- Oramed Pharmaceuticals [...]